Portfolio
2
companies
MicrofluidX
MicrofluidX provides next-generation bioreactors for cell research and manufacturing.
Reacta Biotech
Produces standardised diagnostic kits for clinical food allergy testing.
The funding round was backed by Moulton Goodies, Development Bank of Wales, and Acceleris.
"This investment is a significant step in the development of Reacta Biotech’s business. A combination of seeking our own MHRA approval and the recent FDA approval of the first specific food allergy therapy set to launch in the US soon, creates ideal timing for Reacta to become the only standardised and trusted OFC for all food allergy therapeutics."
The seed round was led by UKI2S and Longwall Ventures to support cell therapy bioprocessing development.
"We are thrilled to close this initial funding round with help from UKI2S. We are continuing to establish partnerships with Biotech and Pharma, on top of our existing partnerships with the Cell and Gene Therapy Catapult and the Centre for Process Innovation. The funding will be used to further develop our technology, as well as fund trials with our partners."
